Altamira Therapeutics company info

What does Altamira Therapeutics do?
Altamira Therapeutics (NASDAQ:CYTO) is a biopharmaceutical company focused on developing novel treatments for diseases related to hearing and balance disorders, as well as therapeutics in the field of RNA (Ribonucleic Acid) interference. The company is dedicated to advancing its pipeline through rigorous scientific research to meet unmet medical needs across various patient populations. Their projects range from early-stage research in gene therapy for hearing loss to developing innovative RNA-based therapeutics targeting specific diseases. Altamira's objective is to improve patients' lives by delivering groundbreaking therapies that address some of the most challenging conditions related to ear health. The company is traded on the NASDAQ stock exchange under the ticker code CYTO, showcasing a commitment to transparency and investor relations as it progresses with its mission in the biopharmaceutical industry.
Altamira Therapeutics company media
Company Snapshot

Is Altamira Therapeutics a public or private company?

key
Ownership
Public

How many people does Altamira Therapeutics employ?

people
Employees
10

What sector is Altamira Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Altamira Therapeutics?

location pin
Head Office
Zug, Switzerland

What year was Altamira Therapeutics founded?

founded flag
Year Founded
2003
What does Altamira Therapeutics specialise in?
/Biopharmaceutical Company /Respiratory Diseases /Tosynra Project /Betulfa Development /Clinical Research /Drug Manufacturing

What are the products and/or services of Altamira Therapeutics?

Overview of Altamira Therapeutics offerings
RNA therapeutics platform focused on developing small interfering RNA (siRNA) treatments for various genetic and age-related hearing impairments.
Nasal spray products designed for fast relief of symptoms related to allergies and common colds, emphasizing ease of use and effectiveness.
Diagnostic tools for precise and early detection of hearing loss, utilizing cutting-edge technologies to improve outcomes and treatment pathways.
Research partnerships with academic and medical institutions to explore novel treatments for ear, nose, and throat (ENT) disorders, fostering innovation and collaborative development.

Who is in the executive team of Altamira Therapeutics?

Altamira Therapeutics leadership team
  • Dr. Thomas  Meyer Ph.D.
    Dr. Thomas Meyer Ph.D.
    Founder, President, Chairman, CEO & MD
  • Mr. Marcel  Gremaud C.P.A.
    Mr. Marcel Gremaud C.P.A.
    Chief Financial Officer
  • Dr. Covadonga  Paneda
    Dr. Covadonga Paneda
    Chief Operating Officer
  • Dr. Samuel A. Wickline M.D.
    Dr. Samuel A. Wickline M.D.
    Chief Scientific Adviser